Last updated: April 26, 2026
Galderma v. Sun (1:18-cv-01588): Litigation Summary and Patent/Exclusivity Posture
What is the case and who are the parties?
- Case: Galderma Laboratories, L.P. v. Sun Pharmaceutical Industries Limited
- Docket: 1:18-cv-01588
- Forum: U.S. District Court (federal)
- Parties:
- Plaintiff: Galderma Laboratories, L.P.
- Defendant: Sun Pharmaceutical Industries Limited
What did Galderma allege?
Galderma’s suit targets Sun’s attempt to market a generic (or generic-style) product that Galderma contends infringes Galderma-held patent rights tied to Galderma’s branded product(s) in the dermatology space. The case is treated as a Hatch-Waxman-style infringement dispute, where the filing posture commonly involves:
- a generic application aligned to a branded reference product,
- certification (Paragraph IV and related provisions) against one or more Orange Book-listed patents, and
- an infringement allegation tied to one or more asserted patents.
Actionable point: The case posture fits the standard IP leverage structure used in patent listing and generic launch timing: Galderma seeks to prevent launch until patent expiration or a court determination that the asserted patents are invalid and/or not infringed.
What is the procedural posture?
The case number and filing year (2018) place it in the period when Hatch-Waxman generic-filing disputes were commonly resolved through:
- early motion practice on jurisdiction/pleading sufficiency and patent eligibility/validity theories,
- claim construction and infringement/invalidity briefing, and
- settlement or final judgment on infringement/invalidity.
No disposition details (final judgment, settlement date, or court order outcome) are provided in the information supplied here; therefore, only the litigation framing and IP risk posture can be stated without overreaching.
What patents and product(s) are implicated?
Which patents are asserted?
The docket number and party names identify the case, but the supplied input does not include:
- the Orange Book listing that drove the dispute,
- the specific asserted patent numbers,
- the asserted claims, or
- the generic product label and NDA/ANDA/RLD reference.
Actionable point: Without the asserted patent numbers and product identifier, the litigation risk cannot be mapped to a specific claim landscape (e.g., formulation vs. method-of-use vs. polymorph vs. composition patents).
What is the likely product category?
Galderma’s dermatology portfolio historically includes:
- prescription dermatologic drugs with formulation and method-of-use IP, and
- pipeline assets where Orange Book listings can include multiple patent families (drug substance, composition, formulation, and use).
Actionable point: The case almost certainly hinges on a drug-specific patent listing rather than a broad technology platform claim, since Hatch-Waxman disputes typically require an Orange Book match.
How does this case affect launch timing and exclusivity?
What is the exclusivity and timing mechanism at issue?
A Hatch-Waxman patent dispute typically impacts:
- the automatic stay triggered by a compliant Paragraph IV filing,
- the effective launch date in relation to patent expiration or court outcome,
- potential design-around strategies if claims are narrowed at claim construction.
Actionable point: Even before merits, the existence of asserted patents listed in the Orange Book often dictates the earliest legally permissible launch path.
What is the practical litigation leverage for Galderma?
With a filed suit against a major generic firm, Galderma’s typical leverage points in this posture are:
- injunction leverage (to delay launch if infringement survives),
- settlement leverage (brand receives value for delayed market entry),
- noninfringement/invalidity burden (generic must overcome both defenses in the chosen theories).
Actionable point: For portfolio planning, the key question is not just infringement, but whether the asserted patents are likely to hold up on validity (anticipation/obviousness) and claim construction.
IP litigation issues to track in Galderma v. Sun
What are the common claim-construction and validity pressure points?
In dermatology formulation and method-of-use patent cases, the recurring “workstreams” in U.S. Hatch-Waxman litigation include:
- construction of functional language (e.g., “effective amount,” “therapeutically effective,” or release/biological activity boundaries),
- composition/formulation parameter mapping (particle size, concentration ranges, pH, excipients, permeability enhancers, release profile),
- method-of-use synchronization with labeling and clinical endpoints,
- prior art selection and motivation to combine (obviousness),
- enablement and written description for formulation ranges and claimed mechanism.
Actionable point: If the asserted patents are formulation- or use-directed, claim scope can hinge on whether the accused product label and manufacturing details map to the claim limitations.
What are the typical damages and remedy dynamics?
When a brand sues a generic under Hatch-Waxman infringement, damages posture often tracks:
- reasonable royalty theory if infringement and no injunction is entered,
- lost profits only if the plaintiff’s market position and sales causation can be proven,
- injunctive relief if the court orders entry restrictions aligned with the asserted patents.
Actionable point: Litigation outcome drives both immediate market entry and longer-horizon settlements across overlapping patents in the same Orange Book listing.
Business and R&D implications
What does this litigation signal for Galderma’s patent strategy?
A brand suing a peer generic manufacturer suggests:
- Galderma treats the asserted patent(s) as enforceable and commercially material,
- the asserted patents are likely central to the branded product’s defensibility and exclusivity story.
Actionable point: Portfolio strategy inference is limited by missing asserted patent numbers and product identifier, so the only reliable takeaway is that Galderma pursued legal enforcement rather than relying solely on regulatory exclusivity.
What does it signal for Sun’s entry risk and design-around options?
For the generic entrant, the existence of litigation indicates:
- a recognized risk that the generic could be enjoined or face settlement-driven delay,
- potential need to pivot to different strengths, different routes, different release systems, or different use instructions if claim scope is read narrowly.
Actionable point: Without the claim limitations and label elements, design-around feasibility cannot be quantified.
Key Takeaways
- Case identity: Galderma Laboratories, L.P. v. Sun Pharmaceutical Industries Limited is filed as 1:18-cv-01588.
- Core dispute type: The case aligns with a Hatch-Waxman patent infringement framework where a brand enforces Orange Book-listed rights against a generic entrant’s market challenge.
- What materially matters for decisions: The decisive drivers are the specific asserted patent numbers, the claim construction outcomes, and the validity theories applied to the accused product and label.
- What is not provided in the supplied information: No docket disposition, no asserted patent list, and no product/NDA-ANDA pairing are included here, so merits, settlement, and exact exclusivity impact cannot be stated from the record provided.
FAQs
1) Is this case a patent infringement action or a regulatory challenge?
It is framed as a U.S. patent infringement dispute in a Hatch-Waxman style posture, brought by a brand against a generic manufacturer.
2) Does the lawsuit automatically delay generic launch?
Hatch-Waxman patent suits commonly create an automatic stay mechanism tied to the generic’s certification posture, but the specific stay outcome depends on the details of filings and court events, which are not included here.
3) What is the fastest way to evaluate commercial impact?
Identify the asserted patent numbers and compare their expiration dates to the generic’s intended launch timeline, then map the likely claim-construction narrowing risks.
4) What usually determines validity outcomes in dermatology formulation/use cases?
Claim scope anchored to product labeling and composition, plus prior art selection and obviousness motivation, and compliance with enablement/written description for claimed ranges.
5) What is Sun’s main litigation exposure?
An adverse judgment can bar or delay launch for the relevant product covered by the asserted claims, and can drive settlement across related patents.
References
[1] Galderma Laboratories, L.P. v. Sun Pharmaceutical Industries Limited, No. 1:18-cv-01588 (U.S. District Court).
